SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Generation Income Properties completed a 1-for-10 reverse stock split effective July 9, 2026, undertaken specifically to regain compliance with Nasdaq Capital Market's minimum bid price requirement of $1.00 per share. The Company disclosed that it was at risk of delisting due to non-compliance with this listing standard and implemented the reverse split as a remedial measure to address this compliance risk.
View raw filing on EDGAR →Mercer International received a written notice from Nasdaq on July 9, 2026, that it failed to comply with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). Although the notice is non-compliance rather than imminent delisting, the Company has been given a 180-day compliance period to regain compliance, with explicit acknowledgment that "there can be no assurance that the Company will be able to regain compliance within the prescribed time period." This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →Lakeside Holding received a second notice from Nasdaq on July 9, 2026, indicating failure to comply with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). While the Company has been granted an additional 180-day compliance period until January 4, 2027, the disclosure explicitly states that if compliance cannot be demonstrated by that date, "the Staff will provide written notification that the Company's securities will be delisted." This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →The filing discloses that Nasdaq notified the Company on May 21, 2026, that it was no longer in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Although the Company raised $4.2 million in a July 1, 2026 offering and believes it now satisfies the requirement, Nasdaq will continue monitoring compliance, and the Company "may be subject to delisting" if it does not evidence compliance by its September 30, 2026 Form 10-Q. This is a classic delisting-risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.
View raw filing on EDGAR →The filing discloses that Autonomix Medical received a deficiency letter on January 14, 2026 for failing the Nasdaq Bid Price Rule (stock below $1.00 per share for 30 consecutive business days), which triggered delisting risk. Although the company subsequently regained compliance by July 9, 2026, the core event disclosed is the prior delisting threat and its resolution. This is material to investors as it reflects the company's historical struggle to maintain listing standards and demonstrates the company was at material risk of delisting.
View raw filing on EDGAR →GeoVax Labs received a notice from Nasdaq on July 7, 2026, that it failed to meet the $2,500,000 minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) and does not meet alternative compliance metrics. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within any extension period granted. This is a direct notice of failure to satisfy a continued listing rule, the core definition of Item 3.01 delisting_risk.
View raw filing on EDGAR →The exhibit announces that Basel Medical Group has regained compliance with Nasdaq's minimum bid price rule (Listing Rule 5550(a)(2)) after receiving a non-compliance notice on January 22, 2026. The company's shares had fallen below the $1.00 minimum bid price threshold but have now maintained $1.00 or greater for 10 consecutive business days. This disclosure directly addresses a delisting risk — the company was previously out of compliance with a continued listing standard and has now cured that deficiency. Material to investors as it resolves an immediate threat to continued listing on Nasdaq.
View raw filing on EDGAR →ENvue Medical received a Staff Determination Letter from Nasdaq on July 10, 2026, notifying the company that its closing bid price has been below $1.00 per share for 30 consecutive business days, violating the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a prior reverse stock split, and while it intends to request a hearing to appeal, there is no assurance of success. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →The Company received a Staff Delisting Determination from Nasdaq on July 7, 2026, notifying it of Nasdaq's determination to delist the Company's securities pursuant to Nasdaq Listing Rule IM-5101-4. The Company intends to appeal by requesting an oral hearing before the Nasdaq Hearings Panel, with no assurance the Panel will find the Company in compliance with listing standards. This is a direct delisting notice triggering the appeal process under Rule 5815.
View raw filing on EDGAR →Prairie received a Nasdaq Minimum Bid Price Notice on July 2, 2026, indicating that its common stock closing bid price has been below the required $1.00 per share for 30 consecutive business days. The company has been granted an initial 180-day compliance period (until December 29, 2026) to regain compliance, with potential delisting consequences if it fails. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →CAE announces a voluntary transfer of its U.S. stock exchange listing from the NYSE to the Nasdaq Global Select Market, effective July 23, 2026. While this is a voluntary transfer rather than an involuntary delisting, it constitutes a material change in listing venue that affects where and how the company's shares trade in the U.S. market. The disclosure explicitly states the last trading day on NYSE (July 22, 2026) and commencement on Nasdaq (July 23, 2026), making this a transfer of listing under Item 3.01 framework, which is material to investors' ability to trade the security.
View raw filing on EDGAR →The filing discloses that ENDRA regained compliance with Nasdaq's Minimum Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)) after initially falling below the $2,500,000 threshold. However, the company is now subject to a one-year Discretionary Panel Monitor period, during which any future non-compliance with Nasdaq Listing Rules will result in immediate delisting without opportunity for a cure period or compliance plan. This represents a material delisting risk that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →Blue Gold has disclosed that it is at risk of delisting from Nasdaq due to failure to meet continued listing requirements, specifically shareholders' equity requirements. The company has undertaken remedial initiatives including balance sheet optimization, shareholder authorization for a reverse split, and potential transfer to Nasdaq Capital Market.
View raw filing on EDGAR →The 6-K discloses that on June 29, 2026, Nasdaq halted trading in the Company's Class A ordinary shares pending satisfaction of Nasdaq's request for additional information, with trading to remain halted until the Company fully complies. This constitutes a material delisting risk under Item 3.01 equivalent, as the trading halt is a precursor to potential delisting and directly threatens the Company's continued listing status on Nasdaq.
View raw filing on EDGAR →Hongli Group received a Nasdaq deficiency notice on July 2, 2026, for failure to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has 180 calendar days (until December 29, 2026) to regain compliance or face potential delisting. The press release explicitly states that if the Company does not cure the deficiency and does not meet eligibility criteria for an extension, "Nasdaq will provide notice that its securities will be subject to delisting." This is a material disclosure of delisting risk under Item 3.01 equivalent.
View raw filing on EDGAR →The filing discloses that Capstone received notice from Nasdaq on July 8, 2026, that it has failed to maintain the minimum $1.00 per share bid price requirement and has been granted an additional 180-calendar-day cure period until January 4, 2027, after which Nasdaq will delist the company's common stock if compliance is not regained. This is a direct delisting risk notification under Nasdaq Listing Rule 5550(a)(2), materially affecting the registrant's continued listing status.
View raw filing on EDGAR →Hydrofarm received a determination letter from Nasdaq on July 2, 2026, stating it failed to meet the terms of an extension to regain compliance with the $2.5 million minimum stockholders' equity requirement (Listing Rule 5550(b)(1)). The company also received notice on July 6, 2026, of non-compliance with the minimum bid price requirement (Listing Rule 5550(a)(2)). While the company requested a hearing that stayed delisting action pending the Panel's decision, the disclosure explicitly addresses failure to satisfy continued listing rules and the material risk of delisting, which is the core substance of Item 3.01.
View raw filing on EDGAR →The filing discloses that AVAX One has regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share) after previously falling below it on March 13, 2026. While the immediate delisting threat has been resolved, the company is now subject to a mandatory one-year panel monitor under Nasdaq Listing Rule 5815(d)(4)(B), during which any future non-compliance will result in immediate delisting without cure periods. This is a material disclosure of delisting risk and continued listing status, as it materially affects the registrant's ability to maintain its public listing and investor confidence.
View raw filing on EDGAR →Beyond Air implemented a 1-for-20 reverse stock split to "raise the per share bid price of the Company's Common Stock above $1.00 per share and bring the Company back into compliance with Nasdaq Listing Rule 5550(a)(2)." This is a direct response to a delisting risk triggered by the stock price falling below the $1.00 minimum bid price requirement. The filing explicitly states the company was out of compliance and needed to regain it, making this a material delisting-risk disclosure.
View raw filing on EDGAR →The filing discloses a Nasdaq Hearings Panel determination to delist Bayview Acquisition Corp's securities effective July 7, 2026, due to failure to complete its business combination with Oabay by the June 19, 2026 deadline. This is a direct delisting notice under Item 3.01, representing a terminal loss of exchange listing and a material adverse event for the registrant and its shareholders.
View raw filing on EDGAR →The filing discloses that Fathom Holdings received a Nasdaq non-compliance notice on April 10, 2026 for failing the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2), but subsequently regained compliance by July 6, 2026 when the closing bid price remained at or above $1.00 for 10 consecutive business days. This is a delisting risk event—the company faced potential delisting but has now cured the deficiency. The disclosure of the initial non-compliance notice and subsequent cure is material to investors assessing the company's listing status and financial condition.
View raw filing on EDGAR →Onfolio Holdings received a written notice from NASDAQ on July 2, 2026, stating non-compliance with NASDAQ Listing Rule 5550(a)(2) due to closing bid price below $1.00 per share for 30 consecutive business days. The company has 180 calendar days to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →The Company disclosed a prior Nasdaq listing compliance matter under Listing Rule 5550(a)(2) regarding the Minimum Bid Price Requirement, with a non-compliance notice issued on February 20, 2026 and a 180-day cure period. The Company regained compliance as of July 2, 2026, though cautionary language indicates no assurance of maintaining future compliance.
View raw filing on EDGAR →NYSE American has accepted Splash Beverage's compliance plan to regain compliance with shareholders' equity requirements, granting a compliance period through January 29, 2027. If the Company fails to regain compliance by that date or does not make progress consistent with the plan, NYSE American may initiate delisting proceedings.
View raw filing on EDGAR →The press release announces a 1-for-10 reverse stock split undertaken "with the objective of meeting the minimum $1.00 per Ordinary Share bid requirement for maintaining the listing of the Ordinary Shares on The Nasdaq Capital Market." This disclosure directly addresses delisting risk — the company is taking corrective action to avoid falling below Nasdaq's continued listing standards. The explicit reference to the minimum bid price requirement and the stated purpose of maintaining listing status are hallmarks of delisting-risk disclosure.
View raw filing on EDGAR →The report discloses that trading in the Company's Class A ordinary shares has been suspended since October 6, 2025, and remains suspended. The Company is furnishing this report to address concerns bearing upon continued listing on The Nasdaq Capital Market. The report outlines multiple remedial measures (re-domiciliation, abolition of dual-class structure, board restructuring, and undertakings regarding foreign private issuer exemptions) intended to restore trading and address delisting risk. This is a material disclosure of delisting risk and suspension of trading, which directly threatens the registrant's continued listing status.
View raw filing on EDGAR →MSP Recovery disclosed that its Class A common stock and publicly traded warrants will be transferred from the OTC Pink Limited Information market tier to the OTC Markets Group's "Expert Market" effective July 17, 2026, due to failure to file delayed annual and quarterly reports (Form 10-K for 2025 and Form 10-Q for Q1 2026). This transfer materially restricts trading availability and liquidity, as Expert Market quotations are limited to unsolicited quotes for sophisticated investors only, representing a significant delisting risk and loss of public market access.
View raw filing on EDGAR →The Company received a Nasdaq minimum bid price deficiency notice on January 22, 2026, triggering a 180-day compliance period ending July 21, 2026. The July 7, 2026 Compliance Letter confirms the Company has regained compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days (June 22–July 6, 2026), resolving the delisting risk. This disclosure directly addresses a continued listing rule failure and its resolution, which is material to investors assessing the registrant's exchange status.
View raw filing on EDGAR →Borealis Foods received a notice from Nasdaq on July 2, 2026, indicating failure to satisfy the minimum Market Value of Listed Securities (MVLS) requirement of $35,000,000 under Nasdaq Listing Rule 5550(b)(2), with no current compliance with alternative standards. The company has a 180-day compliance period (until December 29, 2026) to regain compliance, and faces potential delisting if it fails to do so. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →CEPT notified NASDAQ on July 1, 2026 requesting suspension of trading of its Class A ordinary shares effective July 2, 2026, and filed a Form 25 to delist the shares under Section 12(b) of the Exchange Act. The company intends to file a Form 15 to deregister the shares and suspend SEC reporting obligations.
View raw filing on EDGAR →On July 2, 2026, CEPT Class A Ordinary Shares ceased trading on Nasdaq following the completion of the business combination on July 1, 2026, with the combined entity now trading on NYSE under ticker 'SECZ.'
View raw filing on EDGAR →Blue Gold received written notification from Nasdaq on July 1, 2026, that it failed to meet two continued listing requirements: (1) the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1), and (2) the minimum Market Value of Listed Securities (MVLS) requirement of $50 million under Nasdaq Listing Rule 5450(b)(2). The company has 180 calendar days until December 28, 2026, to regain compliance or face delisting. This is a material disclosure of delisting risk that would significantly affect investor assessment of the registrant's continued public listing status.
View raw filing on EDGAR →RAAQ notified Nasdaq on July 1, 2026 to delist and deregister its Class A Ordinary Shares, Public Warrants, and Units following consummation of the business combination. Nasdaq permanently suspended trading of these securities effective July 2, 2026, with deregistration to become effective 10 days after the Form 25 filing.
View raw filing on EDGAR →Skillsoft disclosed that the NYSE has accepted its compliance plan to regain compliance with continued listing standard 802.01B after the Company fell below minimum thresholds for market capitalization ($50 million) and stockholders' equity ($50 million). The Company has until September 26, 2027 to regain compliance, with explicit warning that failure to comply or meet continued listing standards will trigger "prompt initiation of NYSE suspension and delisting procedures." This is a material delisting-risk disclosure under Item 3.01 framework, even though filed under Item 7.01.
View raw filing on EDGAR →The announcement explicitly states that the 1-for-5 share consolidation is being implemented "to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market." This indicates the company was at risk of delisting due to non-compliance with Nasdaq's minimum bid price rule, and the consolidation is a remedial action to address that delisting risk.
View raw filing on EDGAR →Fusemachines disclosed that on July 7, 2026, it received notification from Nasdaq that it has "regained compliance with Nasdaq Listing Rule 5450(b)(1)(C), which requires the Company to maintain a minimum market value of publicly held shares of $15,000,000." This disclosure directly addresses a delisting risk—the company had previously fallen below the minimum market value threshold and faced potential delisting, but has now remedied that deficiency. The resolution of a listing compliance matter is material to investors assessing the registrant's continued trading status.
View raw filing on EDGAR →Two Hands Corporation voluntarily delisted its common shares from the Canadian Securities Exchange (CSE) effective July 7, 2026. While this is a voluntary delisting (not a forced delisting due to non-compliance), it represents a material change in the registrant's listing status and trading venue. The company's shares continue trading on OTC Markets under "TWOH," but the removal from the CSE is a significant corporate action affecting investor access and liquidity. The filing explicitly states this decision was made after evaluating costs, administrative requirements, and transaction opportunities, indicating a strategic shift in capital markets presence.
View raw filing on EDGAR →The filing discloses that Upland Software has regained compliance with Nasdaq Listing Rule 5450(a)(1) minimum bid price requirement after previously falling below the $1.00 threshold. While the current disclosure is positive (compliance regained), it necessarily implies prior non-compliance with a continued listing rule, which is the material delisting risk event. The letter from Nasdaq dated July 2, 2026 confirms the company met the minimum bid price for 10 consecutive business days and the matter is now closed, resolving the delisting threat.
View raw filing on EDGAR →GreenPower discloses that the British Columbia Securities Commission issued a cease trade order (CTO) on July 6, 2026, due to the Company missing the Canadian filing deadline of June 29, 2026 for its audited annual financial statements and related certifications. While the press release states that Nasdaq trading is not currently impacted, a cease trade order is a regulatory enforcement action that signals potential delisting risk and material non-compliance with securities filing obligations. The disclosure of a CTO is material to investors as it reflects regulatory enforcement and filing delays that could escalate to listing consequences.
View raw filing on EDGAR →NetClass announced a 1-for-50 reverse split effective July 6, 2026, explicitly to "maintain compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to evidence a minimum bid price of $1.00 per share." This is a direct response to delisting risk — the company's stock price had fallen below the $1.00 minimum bid price threshold, triggering the need for a reverse split to avoid delisting from Nasdaq.
View raw filing on EDGAR →The Company received a Nasdaq notification dated July 1, 2026, that it failed to maintain the minimum bid price of US$1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has 180 calendar days (until December 28, 2026) to regain compliance or faces potential delisting. This is a classic delisting-risk disclosure under Item 3.01 equivalent, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →BIO-key's disclosure announces the reinstatement of trading on Nasdaq Capital Market following a June 16th hearing where the Nasdaq Hearings Panel determined the Company "has regained compliance with the continued listing standards, including minimum bid price and SEC filing requirements." This directly addresses a delisting risk event—the company had previously been subject to a trading halt due to non-compliance with listing standards and has now resolved that issue. The materiality is clear: trading suspension and reinstatement materially affect investor access to the stock and the company's market standing.
View raw filing on EDGAR →The exhibit announces that CDT has regained compliance with Nasdaq's minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) after receiving a notice on June 30, 2026 that the closing bid price met or exceeded $1.00 per share for 10 consecutive business days. This disclosure directly addresses a delisting risk — the prior non-compliance with the minimum bid price rule — and announces its resolution. The materiality is high because listing status is fundamental to a public company's continued trading and investor access.
View raw filing on EDGAR →CytoSorbents received a written notice from Nasdaq on June 29, 2026, that it failed to comply with Nasdaq Listing Rule 5550(b)(2) due to its Market Value of Listed Securities falling below the $35 million minimum required for continued listing on the Nasdaq Capital Market. The company has been given a 180-day grace period (until December 28, 2026) to regain compliance, with explicit warning that failure to do so will result in delisting notification and potential loss of listing. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →Canaan announced completion of a transfer from Nasdaq Global Market to Nasdaq Capital Market due to failure to maintain the minimum bid price of $1.00 for 30 consecutive business days. The company received a non-compliance notice on January 14, 2026, and has applied for an additional 180-day compliance period. This disclosure directly addresses delisting risk and the company's efforts to regain compliance with continued listing standards.
View raw filing on EDGAR →Wallbox received a NYSE notice on February 12, 2026 for non-compliance with Section 802.01B regarding average global market capitalization and stockholders' equity. The NYSE has now accepted the Company's compliance plan, granting an 18-month cure period to achieve either $50 million in stockholders' equity or $50 million average market capitalization. This is a material delisting-risk disclosure: the Company faces potential suspension or delisting if it fails to meet the plan milestones, and the announcement explicitly addresses the NYSE's continued listing standards and the conditional nature of ongoing listing.
View raw filing on EDGAR →REE Automotive received a delisting notice from Nasdaq on June 30, 2026, determining that the Company's Class A ordinary shares will be delisted from the Nasdaq Capital Market effective July 7, 2026, due to failure to regain compliance with the Minimum Bid Price Requirement (closing bid price below $1.00 per share for 30 consecutive business days). The Company exhausted its 180-day cure periods and does not intend to request a hearing. This is a terminal delisting determination, not merely a warning or deficiency notice.
View raw filing on EDGAR →The 6-K discloses AXIA Energia's voluntary delisting of its American Depositary Shares (ADSs) from the New York Stock Exchange, effective on or about August 6, 2026, followed by intended deregistration via Form 15F and suspension of SEC reporting obligations. This is a material capital-markets event affecting U.S. investors' ability to trade the company's securities on a major exchange and triggering the end of SEC reporting compliance.
View raw filing on EDGAR →AXIA Energia announced on July 6, 2026, its intention to voluntarily delist all outstanding American Depositary Shares (Common ADSs and Class C Preferred ADSs) from the New York Stock Exchange and withdraw registration under Section 12(b) of the Securities Exchange Act of 1934. While characterized as "voluntary," this is a material delisting event that removes the Company's securities from the primary U.S. trading venue, though shares will continue trading on B3 (Brazil) and in the OTC market via a Level 1 ADR program. This directly affects the liquidity and accessibility of the Company's securities to U.S. investors.
View raw filing on EDGAR →Azul is voluntarily delisting from NYSE American and transferring its listing to the NYSE. While this is a planned, orderly transfer rather than a forced delisting, it constitutes a material change in listing venue that affects how the company's securities trade and the investor base that can access them. The filing explicitly states the company will withdraw from NYSE American and file Form 25 with the SEC, which is the formal delisting mechanism. This is material to investors holding ADSs or common shares on NYSE American.
View raw filing on EDGAR →